Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Recruiting · NCT07660627 · Interventional (participants receive a specific treatment) · Lead sponsor: Masaryk Memorial Cancer Institute
View the official record on ClinicalTrials.gov →Interventions studied
NGS sequencing of mutations selected based on sequencing of primary tumors
What this trial is about
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Consent to participate in the study
- Patients with esophageal, gastric, or pancreatic cancer, stage 0-2
- Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy
- Patients with metastatic disease treated with first- to third-line palliative systemic therapy
Exclusion criteria
- not specified
Where it is running
1 location listed.
- Masaryk Memorial Cancer Institute - Brno, Czechia